Synthesis and characterization of NESS 0327: A novel putative antagonist of the CB1 cannabinoid receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 1, 2003, Pages 363-370

  Ruiu, Stefania ^a   Pinna, Gèrard A ^b   Marchese, Giorgio ^a   Mussinu, Jean Mario ^b   Saba, Pierluigi ^c   Tambaro, Simone ^a   Casti, Paola ^a   Vargiu, Romina ^c   Pani, Luca ^d,e  

^a Neuroscienze PharmaNess Scarl   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d CNR Inst of Neurogenet/N   (Italy)

^e Inst of Neurogenet/Neuropharmacol   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N PIPERIDINYL [8 CHLORO 1 (2,4 DICHLOROPHENYL) 1,4,5,6 TETRAHYDROBENZO[6,7]CYCLOHEPTA[1,2 C]PYRAZOLE 3 CARBOXAMIDE]; NESS 0327; PYRAZOLE DERIVATIVE; RIMONABANT; SULFUR 35; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CEREBELLUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTROSTIMULATION; HOT PLATE TEST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; TAIL FLICK TEST; VAS DEFERENS;

ANIMALS; BINDING, COMPETITIVE; CANNABINOIDS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; MICE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0038340929     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.049924     Document Type: Article

References (36)

1. Abood ME and Martin BR (1992) Neurobiology of marijuana abuse. Trends Pharmacol Sci 13:201-206.
2. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
3. Barth F and Rinaldi-Carmona M (1999) The development of cannabinoid antagonists. Curr Med Chem 6:745-755.
4. 9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271:9902-9905.
5. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594.
9. Compton DR, Jhonson MR, Melvin LS, and Martin BR (1992) Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 260:201-209.
10. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, and Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226.
11. Devane WA, Dysarz FA, Johnson MR, Melvin LS, and Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613.
12. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (Wash DC) 258:1946-1949.
13. Formukong EA, Evans AT, and Evans FJ (1989) The medicinal uses of cannabis and its constituents. Psytother Res 3:219-231.
14. Galiègue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
15. Gralla RJ (1999) Cannabinoids and the control of chemotherapy-induced nausea and vomiting, in Marijuana and Medicine (Nahas GG, Sutin KM, Harvey DJ, and Agurell S eds) pp 599-610, Humana Press, Totowa, NJ.
16. Harris LS and Pierson AK (1964) Some narcotic antagonists in the benzomorphan series. J Pharmacol Exp Ther 143:141-148.
17. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
18. Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607-634.
19. Howlett AC (1998) The CB1 cannabinoid receptor in the brain. Neurobiol Dis 5:405-416.
20. Lichtman AH and Martin BR (1997) The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antininoception in rats. Pharmacol Biochem Behav 57:7-12.
21. Martin BR (1986) Cellular effects of cannabinoids. Pharmacol Rev 38:45-74.
22. Mato S, Pazos A, and Valdizan EM (2002) Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain. Eur J Pharmacol 443:43-46.
23. Mattes RD, Engelman K, Shaw LM, and Elsohly MA (1994) Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 49:187-195.
24. Munro S, Thomas KL, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond) 365:61-65.
25. Nakamura-Palacios EM, Moerschbaecher JM, and Barker LA (1999) The pharmacology of SR 141716A: a review. CNS Drug Rev 5:43-58.
26. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
27. Pertwee RG (1999) Cannabis and cannabinoids: pharmacology and rationale for clinical use. Fortsch Komplementarmed 3:12-15.
28. Pertwee RG, Stevenson LA, and Griffin G (1993) Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol 110:1483-1490.
29. Porcella A, Maxia C, Gessa GL, and Pani L (2001) The synthetic cannabinoid WIN 55,212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur J Neurosci 13:409-412.
30. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
31. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, et al. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
32. Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
33. 35S]thio) triphosphate binding in rat brain membranes. Life Sci 59:659-668.
34. 35S]thio]triphospate binding. Proc Natl Acad Sci USA 92:7242-7246.
35. Vasquez C and Lewis DL (1999) The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 19:9271-9280.
36. Voth EA and Schwartz RH (1997) Medicinal applications of δ-9-tetrahydrocannabinol and marijuana. Ann Intern Med 126:791-798.